This is a clinical trial for men and women with relapsed or refractory multiple myeloma. The main purpose of this study is to test the safety of a new experimental oral drug called CC-122, a Pleiotropic Pathway Modulator (PPM). This class of medication aims to stop the growth of cancerous cells by binding to a protein complex linked to cell division.
SparkCures ID | 209 |
---|---|
Trial Phase | Phase 1 |
Enrollment | 140 Patients |
Treatments |
|
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Exclusion Criteria:
Please visit the ClinicalTrials.gov page for historical site information.
View Centers